Why Did the Young Mother Have Searing Head Pain and a Racing Heart?
The obvious cardiac tests revealed nothing. It wasn ’t until one doctor thought creatively that the culprit was found. (Source: NYT Health)
Source: NYT Health - October 30, 2019 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Tumors pheochromocytoma adrenal glands arrhythmia Source Type: news

Lantheus Takes a Dive into Pharma with Proposed Acquisition
Lantheus Holdings is expanding its presence in the world of radiopharmaceutical diagnostics through a newly-proposed acquisition. On Wednesday, the North Billerica, MA-based company announced it would acquire Progenics Pharmaceuticals, an oncology company developing solutions to find, fight, and follow cancer in an all-stock transaction. The transaction has been unanimously approved by the Boards of Directors of both companies. Under the terms of the agreement, Lantheus Holdings will acquire all of the issued and outstanding common shares of Progenics stock at a fixed exchange ratio. Progenics shareholders will receive 0.2...
Source: MDDI - October 3, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Imaging Source Type: news

Upstate hosts International Conference on Pheo Para
Conference will host what is expected to be the largest single gathering of patients who have battled pheochromocytoma and paraganglioma, a rare condition marked by cancerous tumors. (Source: SUNY Upstate Medical)
Source: SUNY Upstate Medical - June 6, 2019 Category: Universities & Medical Training Source Type: news

CNIO researchers identify a new gene involved in the development of a rare endocrine tumour
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) Paragangliomas and phaeochromocytomas are very rare neuroendocrine tumours and also the most hereditary form of all types of cancer. Researchers have for the first time linked mutations in the DLST gene with the development of such tumors. In addition to the importance of this finding for the future therapies, the discovery can broaden the number of families that may benefit from genetic counselling for prevention, detection and monitoring of these cancers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 28, 2019 Category: Cancer & Oncology Source Type: news

Screening for Neuroendocrine Tumors Is Recommended for NF1 Patients
A study on pheochromocytoma and paraganglioma associated with neurofibromatosis type 1 highlights how screening for these malignancies is important. (Source: CancerNetwork)
Source: CancerNetwork - August 28, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Simple Clinical Factors Predict Metastatic Potential of Neuroendocrine Tumors?
Researchers have developed a clinical prediction model for the metastatic potential of pheochromocytoma and paraganglioma. (Source: CancerNetwork)
Source: CancerNetwork - August 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA Approves Iobenguane I 131 for Rare Adrenal Gland Tumors
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

FDA approves Progenics' drug for rare tumors
The drug, Azedra, was approved to treat patients above the age of 12 who have either of the two tumors, pheochromocytoma or paraganglioma, and require anti-cancer therapy (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 31, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Azedra for Rare Adrenal Tumors
TUESDAY, July 31, 2018 -- Azedra (iobenguane) has been approved by the U.S. Food and Drug Administration to treat people 12 and older with rare adrenal gland tumors (pheochromocytoma or paraganglioma) that can't be surgically removed and have spread... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 31, 2018 Category: Pharmaceuticals Source Type: news

FDA approves first non-surgical treatment for 2 rare cancers
The Food and Drug Administration on Tuesday approved the first ever non-surgical treatment for the rare neuroendocrine cancers: pheochromocytoma and paraganglioma. The approval for Azedra, a drug developed by Progenics Pharmacecuticals of Tarrytown, N.Y., was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania in Philadelphia. “This is a true breakthrough," said Dr. Daniel A. Pryma, an associate professor of radiology and radiation… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 31, 2018 Category: American Health Authors: John George Source Type: news

Therapy for Rare Cancers receives FDA approval following trials at Penn's Abramson Cancer
(University of Pennsylvania School of Medicine) The US Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 31, 2018 Category: Cancer & Oncology Source Type: news

FDA Approves Drug for Rare Adrenal Tumors
(MedPage Today) -- Iobenguane I 131 active in pheochromocytoma, paraganglioma (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - July 30, 2018 Category: Primary Care Source Type: news

FDA Approves Azedra (iobenguane I 131) for Rare Adrenal Tumors
July 30, 2018 -- The U.S. Food and Drug Administration today approved Azedra (iobenguane I 131) injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2018 Category: Drugs & Pharmacology Source Type: news

Pheochromocytoma/Paraganglioma and Cancer Metabolism Pheochromocytoma/Paraganglioma and Cancer Metabolism
A better understanding of the metabolic pathophysiology in pheochromocytomas/paragangliomas may lead to more targeted treatment for these tumors.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Pheochromocytoma: A Genetic and Diagnostic Update Pheochromocytoma: A Genetic and Diagnostic Update
Improved diagnostic tools offer earlier and more accurate detection of pheochromocytomas and paragangliomas.Endocrine Practice (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 5, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Penn-led trial shows AZEDRA can be effective, safe for treatment of rare neuroendocrine tumors
(University of Pennsylvania School of Medicine) A radiotherapy drug that treats the rare neuroendocrine cancers pheochromocytoma and paraganglioma can be both effective and safe for patients, according to the findings of a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2018 Category: Cancer & Oncology Source Type: news

Carvedilol Helps Protect Heart During PPGL Surgery
(MedPage Today) -- Med offers superior blocking for cardiac complications in pheochromocytoma (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 23, 2018 Category: Cardiology Source Type: news

Cabozantinib Promising in Malignant Adrenal Gland Tumors
(MedPage Today) -- Longer PFS in patients with pheochromocytomas, paragangliomas (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - May 21, 2018 Category: Endocrinology Source Type: news

Cabozantinib Looks Promising for Malignant Pheochromocytoma Cabozantinib Looks Promising for Malignant Pheochromocytoma
Tyrosine kinase inhibitor may offer several benefits to patients with malignant pheochromocytomas and paragangliomas, very rare forms of cancer that are difficult to treat.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 19, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

What Causes Flushing?
Discussion Flushing is usually thought of as a benign condition such as blushing, but can be quite irritating if it is frequent or persistent (i.e. menopausal hot flashes) or even pathologic (i.e. malignancy). “Flushing is a subjective and sensation of warmth that is accompanied by reddening of the skin anywhere on the body but favors the face, neck, and upper torso…. Flushing can be broadly divided into episodic or persistent. Episodic flashing is mediated by the release of endogenous vasoactive mediators or medications, while persistent flushing result in a fixed facial erythema with telangiectasias and cyan...
Source: PediatricEducation.org - April 30, 2018 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Aspects of SDHA-Related Pheochromocytoma and Paraganglioma Aspects of SDHA-Related Pheochromocytoma and Paraganglioma
A better understanding of germline SDHA variants and mutations may allow for the earlier detection of paragangliomas.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Pheochromocytoma Surgery Pretreatments Both'Quite Good'Pheochromocytoma Surgery Pretreatments Both'Quite Good '
Phenoxybenzamine and doxazosin found equally effective in maintaining hemodynamic control during resection in PRESCRIPT trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 18, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA(R) (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 -- (Healthcare Sales & Marketing Network) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the... Biopharmaceuticals, Oncology, FDA Progenics Pharmaceuticals, AZEDRA, iobenguane, Pheochromocytoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 29, 2017 Category: Pharmaceuticals Source Type: news

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 29, 2017 Category: Drugs & Pharmacology Source Type: news

Progenics Pharmaceuticals Completes Submission of NDA for Azedra (iobenguane I 131) in Pheochromocytoma and Paraganglioma
NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it has completed the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - November 2, 2017 Category: Drugs & Pharmacology Source Type: news

Pheochromocytoma and Paraganglioma in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - October 26, 2017 Category: General Medicine Source Type: news

Medical News Today: Pheochromocytoma: Symptoms, diagnosis, and treatment
What is pheochromocytoma and what is the adrenal gland? In this article, learn about the causes of pheochromocytoma and its potential complications. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 3, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Preoperative Management for Phaeochromocytoma/Paraganglioma Preoperative Management for Phaeochromocytoma/Paraganglioma
Find out what the available evidence tells us about the preoperative management of patients with phaeochromocytomas and paragangliomas.Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 22, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

New study links'mastermind' gene to rare cancer-causing tumor
Scientists have discovered a new " mastermind fusion gene " may be associated with a rare cancer-causing tumor -- pheochromocytomas ( " pheo " ) and paragangliomas -- according to a study. This breakthrough discovery could lead to more precise treatment as well as a better understanding of cancer itself. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 13, 2017 Category: Science Source Type: news

In-depth gene search reveals new mutations, drug targets in rare adrenal tumors
(University of Pennsylvania School of Medicine) Casting one of the largest genomic nets to date for the rare tumors of the autonomic nervous system known as pheochromocytoma and paraganglioma (PCC/PGL) captured several new mutations driving the disease that could serve as potential drug targets, researchers from Penn Medicine and other institutions reported this week in Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 13, 2017 Category: Global & Universal Source Type: news

Pheochromocytoma
Title: PheochromocytomaCategory: Diseases and ConditionsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 9/6/2016 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - September 6, 2016 Category: Cardiology Source Type: news

Study identifies important predictors for PC/PGL
BALTIMORE – Tumor size and the presence of mutations of the succinate dehydrogenase complex subunit B (SDHB) gene may be reliable indicators of prognosis after surgery for pheochromocytoma and... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - July 13, 2016 Category: Endocrinology Source Type: news

Perioperative Care of PhaeochromocytomaPerioperative Care of Phaeochromocytoma
This article reviews the essentials of perioperative care and monitoring in patients with pheochromocytomas and paragangliomas. BJA Education (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 7, 2016 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Adrenoceptor Blockade for Hormonally Functional Pheo/PGLAdrenoceptor Blockade for Hormonally Functional Pheo/PGL
A new study examines whether patients with hormonally functional pheochromocytomas and paragangliomas (pheo/PGLs) are receiving the appropriate pharmacological treatment. Clinical Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 5, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Published in Hormone and Metabolic Research, a study found that paediatric patients with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times more likely to also carry a diagnosis of ADHD. Clinical Endocrinology News (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 20, 2016 Category: Endocrinology Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - May 19, 2016 Category: Endocrinology Source Type: news

Adrenal gland tumors linked to ADHD diagnosis
Pediatric patients diagnosed with pheochromocytomas (PHEO) or paragangliomas (PGL) were nearly three times as likely to also carry a diagnosis of attention deficit hyperactivity disorder (ADHD),... (Source: Pediatric News)
Source: Pediatric News - May 19, 2016 Category: Journals (General) Source Type: news

Quantification of Metanephrine and Normetanephrine in Urine Using Liquid Chromatography-Tandem Mass Spectrometry
Measuring urinary metanephrines aides in the diagnosis of pheochromocytomas–catecholamine producing tumors. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) allows for greater sensitivity and simpler sample preparation as compared with other techniques. Here we describe a simple LC-MS/MS method for measuring metanephrines in urine. Each urine sample was treated with diphenylboronic acid to create boronate complexes, and then applied to a Bond-Elut Plexa cartridge. After solid phase extraction, samples were concentrated and analyzed on an Atlantis T3 column with chromatographic run time totaling 8.5 min. MS/M...
Source: Springer protocols feed by Imaging/Radiology - November 27, 2015 Category: Radiology Source Type: news

Quantitation of Free Metanephrines in Plasma by Liquid Chromatography-Tandem Mass Spectrometry
We describe here a liquid chromatography-tandem mass spectrometry method to measure free metanephrines in plasma. Free metanephrine and normetanephrine are extracted via solid-phase extraction. After extraction and evaporation, the reconstituted supernatant is analyzed by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS). The MS/MS is set to selective reaction monitoring mode (180.1 → 148.1 m/z for metanephrine, 183.1 → 168.1 for d3-metanephrine, 166.1 → 134.1 m/z for normetanephrine, and 169.1 → 137.2 ...
Source: Springer protocols feed by Imaging/Radiology - November 27, 2015 Category: Radiology Source Type: news

Sharpen your USMLE skills with this top missed test prep question
A top priority for medical students is preparing for the United States Medical Licensing Exam (USMLE), which is why each month, we’re giving you an exclusive scoop on the most challenging USMLE questions and expert strategies to help you beat them. This month’s question explores pathophysiology. Think you know the answer? Check out the question that stumped most of your peers—and hear an expert video explanation of the answer from Kaplan Medical. Welcome to the second post in AMA Wire’s series, “Tutor talk: Tips from Kaplan on the most missed USMLE questions.” Each month, we’ll r...
Source: AMA Wire - October 20, 2015 Category: Journals (General) Authors: amamod Source Type: news

Adrenal-Sparing Surgery Better for PheochromocytomaAdrenal-Sparing Surgery Better for Pheochromocytoma
Patients with MEN2 and pheochromocytoma who have adrenal-sparing surgery as opposed to adrenalectomy show similar recurrence rates at 10 years of follow-up, but importantly retain adrenal function. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - May 27, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Pheochromocytoma Therapeutic Pipeline Review H1 2015 Market Research...
RnRMarketResearch.com adds “Pheochromocytoma – Pipeline Review, H1 2015” to its store. The report provides an overview of the Pheochromocytoma’s therapeutic pipeline.(PRWeb May 20, 2015)Read the full story at http://www.prweb.com/releases/pheochromocytoma-pipeline/review-h1-2015-market/prweb12733418.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 20, 2015 Category: Pharmaceuticals Source Type: news